Developing a Solution

Phase 3 Trials Are Underway

For people with diabetes who use insulin, we know how difficult it is to maintain blood glucose levels within a certain range. So too, is predicting when low blood sugar can happen. In the case of severe hypoglycemia, it can lead to serious medical complications, including seizures, coma, and even a risk of death.

People experiencing a severe hypoglycemic episode cannot self-administer the lifesaving medication they need: glucagon, a hormone that causes the liver to release glucose into circulation. Instead, they are left to depend on a broad safety net of family, friends, coworkers, schoolteachers, and even bystanders to act in an emergency by rescuing them with glucagon.

It is essential that people with diabetes who use insulin and those that surround them are prepared, confident, and empowered to take action in the event of severe hypoglycemia.

We are working diligently to place our novel glucagon rescue treatment in the hands of people who use insulin and those who touch their lives. Study results have been positive to date. Data from our phase 3 clinical trials have started to be presented at conferences around the world.

View press releases
The Word Is Out

Follow these links to see reporters' and bloggers' coverage of Locemia and its glucagon nasal powder (GNP).